10x Genomics Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
10x Genomics (TXG) Tops Q1 EPS by 16c, Revenues Beat; Offers FY21 Revenues Mid-Point Guidance Below Consensus
May 5, 2021 4:36 PM EDT10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.11), $0.16 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $105.8 million versus the consensus estimate of $102.51 million.
Recent Highlights
Revenue was $105.8 million for the first quarter, representing a 47% increase over the corresponding period of... More